Find Out if You Qualify for a Financial Reward by filling out the form below.
Investigation Details
4D Molecular Therapeutics released the interim results of its Phase 2 PRISM study on Intravitreal 4D-150 on July 17, 2024. Despite the Company billing the results as positive, the stock fell by more than 35.8% in afternoon trading on the same day. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
| Ticker Symbol | Company Name | Join Deadline | |
|---|---|---|---|
| NSSC | Napco Security Technologies, Inc. | June 24, 2025 | Join |
| NSSC | Napco Security Technologies, Inc. | June 24, 2025 | Join |
| NSSC | Napco Security Technologies, Inc. | June 24, 2025 | Join |
| CODI | Compass Group Diversified Holdings, LLC | July 08, 2025 | Join |
| IOVA | Iovance Biotherapeutics, Inc. | July 14, 2025 | Join |
| OGN | Organon & Co. | July 22, 2025 | Join |
| VSTS | Vestis Corporation | August 08, 2025 | Join |
| RCKT | Rocket Pharmaceuticals, Inc. | August 11, 2025 | Join |